The 2018 ESMO congress report includes the latest advancements of checkpoint inhibitors, which excel in all treatment lines of lung cancer therapies, aswell as novel potent treatment options for ALK- and MET-positive disease. Additionally, this report focuses on what is new with respect to activity andresistance of EGFR TKIs in EGFR-mutantlung cancer. 

Expert Interview:

Sanjay Popat talks aboutmodern chemotherapeutic treatment options for patients withsquamous NSCLC, the benefits of combining immunotherapies withchemotherapy and the use of liquid biopsy for metastatic NSCLC inclinical practice today.

The memo inOncology Special Issue report is produced by Springer, as a supplement ofmemo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim with anunrestricted educational grant. For more information on the memo inOncologySpecial Issue series, and for free access to all previous editions, visit the memo-inOncologywebsite.

Access an articledirectly:

● Preface

‍

● Checkpoint inhibition excels in all treatment lines

● EGFR-mutant lung  cancer: what’s new with respect to activity and resistance?

● Interview: Several reasons support sequencing of EGFR TKI treatment

● Potent treatment options in ALK– and MET-positive disease

● Full Report (English)

Downloadthe full report (English)